Skip to main content
Precision OncologyPancreatic Cancer· 6 min read· in Health

Pan-RAS Molecular Glue ERAS-0015 Shows Early Efficacy in Lung and Pancreatic Tumors

An experimental daily pill called ERAS-0015 has demonstrated significant tumor shrinkage in heavily pretreated patients with advanced lung and pancreatic cancers. The pan-RAS molecular glue achieved response rates up to 69 percent in specific pancreatic cancer subtypes during early clinical testing.

By Arjun Malhotra

Share this story

Listen

An experimental daily pill has demonstrated the ability to significantly shrink tumors in patients with advanced lung and pancreatic cancers who had exhausted other treatments. The drug, ERAS-0015, achieved response rates as high as 69 percent in specific pancreatic cancer subtypes during early clinical testing.[1][2]

Researchers presented the updated Phase 1 data from the AURORAS-1 clinical trial on November 20 at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. The findings offer a new therapeutic avenue for cancers driven by RAS genetic mutations.[1][4]

RAS mutations drive approximately 19 percent of all human cancers, including some of the most aggressive and treatment-resistant forms of pancreatic ductal adenocarcinoma and non-small cell lung cancer. For decades, these mutations were considered undruggable due to the protein's smooth surface, which lacks obvious binding pockets for traditional medications.[1][4]

Historically, the only successful RAS inhibitors were designed exclusively for the KRAS G12C mutation, which accounts for a fraction of lung cancers and very few pancreatic cases. This left the vast majority of patients with RAS-driven tumors entirely reliant on conventional chemotherapy.[1][4]

Targeting the Active Switch

ERAS-0015 bypasses this structural challenge by functioning as a pan-RAS molecular glue. The drug is designed to bind to the RAS protein only when it is in its active, GTP-bound state, effectively shutting down the cellular signaling pathways that drive uncontrolled tumor growth.[1][4]

Certain RAS mutations work like a switch that is locked in the 'on' position, continuously conveying signals that lead to and sustain cancer, researchers noted at the symposium. ERAS-0015 binds to this switch while it is engaged, blocking the downstream signals across multiple distinct cancer-driving alterations.[1][4]

Confirmed objective response rates observed at the 32-milligram daily dose in the AURORAS-1 Phase 1 trial.

The clinical results in pancreatic cancer were particularly notable given the heavily pretreated patient population. Among patients with KRAS G12X mutations who received 32 milligrams of the drug once daily, 44 percent experienced confirmed objective tumor shrinkage.[1][3]

Within that pancreatic cancer group, 84 percent of the patients were receiving ERAS-0015 as their third-line treatment or later. Despite their advanced disease stage, the molecular glue successfully halted tumor progression and reduced tumor volume in nearly half of the cohort.[3]

The response rates climbed even higher for specific genetic profiles. Among pancreatic cancer patients harboring KRAS G12D or G12V mutations—which together account for nearly 70 percent of all pancreatic ductal adenocarcinomas—the confirmed objective response rate reached 69 percent at the 32-milligram dose.[3]

Efficacy in Lung Cancer

The drug demonstrated similar efficacy in advanced non-small cell lung cancer. Patients with KRAS G12X mutations who had previously progressed after receiving both immune checkpoint inhibitors and platinum-based chemotherapy achieved a 60 percent confirmed objective response rate.[1][3]

Dr. Judy Wang, a medical oncologist at Florida Cancer Specialists and Research Institute, emphasized the clinical relevance of these figures for patients facing terminal diagnoses. She noted that the AURORAS-1 trial specifically enrolled individuals who had already tried and failed multiple standard therapies.[1][4]

In this context, ERAS-0015 treatment caused a 44 percent response rate in patients with RAS-mutant pancreatic cancer and a 60 percent response rate in patients with RAS-mutant lung cancer, Wang told the Barcelona symposium.[1][4]

A response means the patients experienced considerable tumour shrinkage, and these response rates are important as they show clinically meaningful activity from ERAS-0015 treatment in patient groups that have few if any therapeutic options to address their cancer, Wang explained.[1][4]

Safety data from the 122 patients treated at pharmacologically active doses of 16 to 32 milligrams showed the compound was generally well tolerated. The most frequently reported adverse side effects were low-grade rash, diarrhea, nausea, and inflammation of the mouth lining.[1][3]

Pancreatic cancer remains one of the most difficult malignancies to treat, making the early response rates highly significant.

Safety and Combination Potential

Severe complications were relatively rare for an advanced cancer therapy. Only 12 patients, representing 9.8 percent of the cohort, reported grade 3 or higher treatment-related adverse events. Crucially, researchers observed no dose-limiting toxicities at the 32-milligram daily dose.[1][4]

The favorable safety profile and low rates of dose interruptions or discontinuations suggest that patients can maintain the treatment long enough to benefit from its tumor-shrinking effects. All patients who achieved a response at the 32-milligram dose remained on the treatment as of the data cutoff.[3]

Beyond its use as a standalone therapy, the AURORAS-1 trial is evaluating ERAS-0015 in combination with established cancer treatments, including pembrolizumab and panitumumab. Early data indicates that the molecular glue can be safely paired with these drugs without generating unexpected safety signals.[3][5]

The combination cohorts are particularly important for moving the drug into earlier lines of treatment. By pairing ERAS-0015 with standard-of-care immunotherapies or chemotherapies, oncologists hope to strike the cancer from multiple angles simultaneously, potentially preventing the tumor from adapting.[3][5]

In laboratory studies, ERAS-0015 demonstrated an 8- to 20-fold higher binding affinity to cyclophilin A compared to earlier molecular glue candidates. This stronger binding translates to a longer residence time in tumor tissues, allowing the drug to maintain its signaling blockade more effectively.[2][3]

Accelerating Clinical Timelines

The drug is also designed to inhibit wild-type RAS variants alongside the mutated versions. This dual action may help prevent the cancer cells from developing resistance to the treatment, a common failure point for earlier generation, mutation-specific targeted therapies.[2][3]

Based on the robust Phase 1 data, Erasca, the clinical-stage precision oncology company developing the drug, announced plans to significantly accelerate its clinical development timeline. The company is moving directly toward late-stage trials that could support regulatory approval.[3]

Unlike earlier targeted therapies, molecular glues can bind to the smooth surface of the RAS protein by utilizing cyclophilin A.

Erasca plans to initiate a potentially registration-enabling trial for patients with second-line or later RAS-mutant non-small cell lung cancer in the first half of 2027. A Phase 3 trial for first-line lung cancer is scheduled to follow between late 2027 and early 2028.[3]

For pancreatic cancer, the company is accelerating the initiation of a Phase 3 trial in the first-line setting to the first half of 2027. ERAS-0015 has already received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of metastatic pancreatic adenocarcinoma.[3]

The rapid progression from Phase 1 dose-escalation to planned Phase 3 trials reflects the urgent unmet medical need in these cancer types. Pancreatic cancer, in particular, has a five-year survival rate of just 13 percent, largely because it is typically diagnosed at an advanced stage.[1][4]

A Shift in Precision Oncology

The AURORAS-1 trial design reflects a modern, biomarker-driven approach to clinical research. Rather than grouping patients solely by where their cancer originated in the body, the study enrolls participants based on the specific genetic mutations driving their disease, allowing for a more targeted evaluation.[4][5]

The emergence of pan-RAS molecular glues represents a fundamental shift in precision oncology. By targeting the active state of the protein rather than relying on specific structural pockets, researchers are finally able to drug the mutations that drive nearly a fifth of all human malignancies.[1][2]

The emergence of pan-RAS molecular glues represents a fundamental shift in precision oncology.

As the AURORAS-1 trial continues to enroll patients across multiple solid tumor cohorts, the upcoming 2027 trials will provide the definitive data needed to confirm whether these early tumor shrinkage rates translate into extended overall survival for patients.[3][5]

Key points

  • ERAS-0015 achieved a 44 percent confirmed response rate in heavily pretreated pancreatic cancer patients with KRAS G12X mutations.
  • The response rate reached 69 percent for pancreatic cancer patients harboring specific KRAS G12D or G12V mutations.
  • Patients with advanced non-small cell lung cancer experienced a 60 percent confirmed response rate after exhausting other therapies.
  • The drug was generally well tolerated at the 32-milligram daily dose, with no dose-limiting toxicities reported.

What we don’t know

  • It remains unclear whether the initial tumor shrinkage observed in Phase 1 will translate into significantly extended overall survival.
  • The long-term safety profile and potential for acquired resistance over extended treatment periods have not yet been established.
Clinical Oncologists 40%Drug Developers 40%Clinical Researchers 20%
Clinical Oncologists
Focus on the immediate clinical benefit for patients who have exhausted all standard lines of therapy.
Drug Developers
Emphasize the structural breakthrough of drugging the active RAS state across multiple mutation variants.
Clinical Researchers
Prioritize establishing the safety profile and optimal dosing for broader application in combination therapies.

Perspectives this story doesn't cover

  • Patient advocacy groups
  • Health economists evaluating future treatment costs

Sources

Source coverage

5 outlets

3 viewpoints surfaced

Clinical Oncologists 40%Drug Developers 40%Clinical Researchers 20%
  1. [1]EORTCClinical Oncologists

    'Pan-RAS molecular glue' is a safe and effective treatment for lung and pancreatic cancers: results from AURORAS-1 clinical trial

    Read on EORTC →
  2. [2]Bioengineer.orgDrug Developers

    Molecular Glue ERAS-0015 Shows Early Tumour Shrinkage in Phase I Cancer Trial

    Read on Bioengineer.org →
  3. [3]Investing.comDrug Developers

    Erasca reports updated Phase 1 data for ERAS-0015 and ERAS-4001 in solid tumors

    Read on Investing.com →
  4. [4]ecancerClinical Oncologists

    Results from the AURORAS-1 phase I clinical trial of an anti-cancer drug called ERAS-0015

    Read on ecancer →
  5. [5]ClinicalTrials.govClinical Researchers

    A Study of ERAS-0015 in Patients With Advanced Solid Tumors (AURORAS-1)

    Read on ClinicalTrials.gov →
Listen

Comments

Stay informed

Every angle. Every day.

Get Health stories with full source coverage and perspective breakdowns, free every day.